ANG II receptor blockade enhances anti-inflammatory macrophages in anti-glomerular basement membrane glomerulonephritis

American Journal of Physiology - Renal Physiology

Volumn 298, Issue 4, 2010, Pages

  Aki, Kaoru ^a   Shimizu, Akira ^a   Masuda, Yukinari ^a   Kuwahara, Naomi ^a   Arai, Takashi ^a   Ishikawa, Arimi ^a   Fujita, Emiko ^a   Mii, Akiko ^a   Natori, Yasuhiro ^b   Fukunaga, Yoshitaka ^a   Fukuda, Yuh ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; CREATININE; GAMMA INTERFERON; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG MEGADOSE; GLOMERULONEPHRITIS; HISTOPATHOLOGIC SKIN REACTION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATION; INTERFERON PRODUCTION; LOW DRUG DOSE; MACROPHAGE ACTIVATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; TRANSMISSION ELECTRON MICROSCOPY;

EID: 77950855431     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00374.2009     Document Type: Article

References (54)

1. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 6: 137-143, 2007.
2. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 116: 263-272, 2004.
3. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 355: 637-645, 2000.
4. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 21: 20-27, 2007.
5. Dijkstra CD, Dopp EA, Joling P, Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 54: 589-599, 1985.
6. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65: 30-39, 2004.
7. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45: 154-162, 2006.
8. Erwig LP, Kluth DC, Rees AJ. Macrophages in renal inflammation. Curr Opin Nephrol Hypertens 10: 341-347, 2001.
9. Fearon WF, Fearon DT. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation 117: 2577-2579, 2008.
10. Ferenbach D, Kluth DC, Hughes J. Inflammatory cells in renal injury and repair. Semin Nephrol 27: 250-259, 2007.
11. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 3: 23-35, 2003.
12. Griffin KA, Bidani AK. Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin J Am Soc Nephrol 1: 1054-1065, 2006.
13. Grinberg S, Hasko G, Wu D, Leibovich SJ. Suppression of PLCβ2 by endotoxin plays a role in the adenosine A2A receptor-mediated switch of macrophages from an inflammatory to an angiogenic phenotype. Am J Pathol 175, 2439-2453, 2009.
14. Hashimoto S, Suzuki T, Dong HY, Nagai S, Yamazaki N, Matsushima K. Serial analysis of gene expression in human monocyte-derived dendritic cells. Blood 94: 845-852, 1999.
15. Ihm CG, Jeong KW, Lee SH, Lee TW, Park JK. Effects of therapeutic agents on the inflammatory and fibrogenic factors in IgA nephropathy. Nephrology (Carlton) 12, Suppl 3: S25-S26, 2007.
16. Ikezumi Y, Suzuki T, Hayafuji S, Okubo S, Nikolic-Paterson DJ, Kawachi H, Shimizu F, Uchiyama M. The sialoadhesin (CD169) expressing a macrophage subset in human proliferative glomerulonephritis. Nephrol Dial Transplant 20: 2704-2713, 2005.
17. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW, Matsushima K, Yoshie O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 11: 81-88, 1999.
18. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 72: 184-190, 2006.
19. Isome M, Fujinaka H, Adhikary LP, Kovalenko P, El-Shemi AG, Yoshida Y, Yaoita E, Takeishi T, Takeya M, Naito M, Suzuki H, Yamamoto T. Important role for macrophages in induction of crescentic anti-GBM glomerulonephritis in WKY rats. Nephrol Dial Transplant 19: 2997-3004, 2004.
20. Kambayashi T, Jacob CO, Strassmann G. IL-4 and IL-13 modulate IL-10 release in endotoxin-stimulated murine peritoneal mononuclear phagocytes. Cell Immunol 171: 153-158, 1996.
21. Kawasaki K, Yaoita E, Yamamoto T, Kihara I. Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats. Kidney Int 41: 1517-1526, 1992.
22. Kitching AR, Holdsworth SR, Tipping PG. Crescentic glomerulonephritis - a manifestation of a nephritogenic Th1 response? Histol Histopathol 15: 993-1003, 2000.
23. Kluth DC, Erwig LP, Rees AJ. Multiple facets of macrophages in renal injury. Kidney Int 66: 542-557, 2004.
24. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC. Local macrophage proliferation in the pathogenesis of glomerular crescent formation in rat anti-glomerular basement membrane (GBM) glomerulonephritis. Clin Exp Immunol 110: 233-240, 1997.
25. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 16: 966-976, 2005.
26. Mantovani A, Locati M, Vecchi A, Sozzani S, Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol 22: 328-336, 2001.
27. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686, 2004.
28. Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 3: 1-33, 2006.
29. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 13: 453-461, 2008.
30. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 159: 599-608, 2001.
31. Mii A, Shimizu A, Masuda Y, Ishizaki M, Kawachi H, Iino Y, Katayama Y, Fukuda Y. Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression. Lab Invest 89: 164-177, 2009.
32. Moriuchi A, Yamasaki H, Shimamura M, Kita A, Kuwahara H, Fujishima K, Satoh T, Fukushima K, Fukushima T, Hayakawa T, Mizuguchi H, Nagayama Y, Abiru N, Kawasaki E, Eguchi K. Induction of human adiponectin gene transcription by telmisartan, angiotensin receptor blocker, independently on PPAR-gamma activation. Biochem Biophys Res Commun 356: 1024-1030, 2007.
33. Mosser DM. The many faces of macrophage activation. J Leukoc Biol 73: 209-212, 2003.
34. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969, 2008.
35. Ohashi R, Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N. Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol 13: 1795 - 1805, 2002.
36. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 17: 537-545, 1999.
37. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of reninangiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 68: S57-S65, 2005.
38. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 118: 3522-3530, 2008.
39. Ruilope LM, Jakobsen A, Heroys J, Ralph A, Rees T, Shaw M. Prospects for renovascular protection by more aggressive renin-angiotensin system control. Medscape J Med Suppl 10: S5, 2008.
40. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proin-flammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001.
41. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 17: 2985-2991, 2006.
42. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 18: 2439-2446, 2007.
43. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 18: 720-730, 2005.
44. Schreiner GF. The role of the macrophage in glomerular injury. Semin Nephrol 11: 268-275, 1991.
45. Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N. Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis. Am J Pathol 151: 1231-1239, 1997.
46. Shimizu A, Masuda Y, Mori T, Kitamura H, Ishizaki M, Sugisaki Y, Fukuda Y. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat antiglomerular basement membrane glomerulonephritis. J Am Soc Nephrol 15: 2655-2665, 2004.
47. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176: 287-292, 1992.
48. Sugimoto K, Kazdova L, Qi NR, Hyakukoku M, Kren V, Simakova M, Zidek V, Kurtz TW, Pravenec M. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. J Hypertens 26: 1209-1215, 2008.
49. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 35: 881-900, 2003.
50. Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 154: 247-254, 2008.
51. Walcher D, Hess K, Heinz P, Petscher K, Vasic D, Kintscher U, Clemenz M, Hartge M, Raps K, Hombach V, Marx N. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension 51: 259-266, 2008.
52. Wang Y, Wang YP, Zheng G, Lee VW, Ouyang L, Chang DH, Mahajan D, Coombs J, Wang YM, Alexander SI, Harris DC. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 72: 290-299, 2007.
53. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914-1919, 2006.
54. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 7: 463-469, 2007.